Larimar Therapeutics, Inc. Stock 12‑Month Price Target Cut to $13.62, Implies 399% Upside
Less than 1 min read
- According to estimates from 8 analysts, Larimar Therapeutics, Inc. stock's average price target has fallen from $14.4 to $13.62, with forecasts ranging from $5 to $25 per share
- Based on the Nov. 11 closing price, the updated target implies approximately 399% potential upside
- Consensus rating remains at “Buy” across 9 covering analysts, with 9 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Larimar Therapeutics, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Larimar Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.